- Home
- ODV vs DMAC Comparison
ODV vs DMAC Comparison
Compare ODV & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- DMAC
- Stock Information
- Founded
- ODV 2005
- DMAC 2000
- Country
- ODV Canada
- DMAC United States
- Employees
- ODV N/A
- DMAC N/A
- Industry
- ODV Precious Metals
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- DMAC Health Care
- Exchange
- ODV Nasdaq
- DMAC Nasdaq
- Market Cap
- ODV 338.9M
- DMAC 310.1M
- IPO Year
- ODV N/A
- DMAC N/A
- Fundamental
- Price
- ODV $2.87
- DMAC $6.87
- Analyst Decision
- ODV
- DMAC Strong Buy
- Analyst Count
- ODV 0
- DMAC 3
- Target Price
- ODV N/A
- DMAC $12.33
- AVG Volume (30 Days)
- ODV 1.3M
- DMAC 448.5K
- Earning Date
- ODV 11-11-2025
- DMAC 11-12-2025
- Dividend Yield
- ODV N/A
- DMAC N/A
- EPS Growth
- ODV N/A
- DMAC N/A
- EPS
- ODV N/A
- DMAC N/A
- Revenue
- ODV $5,147,156.00
- DMAC N/A
- Revenue This Year
- ODV $317.30
- DMAC N/A
- Revenue Next Year
- ODV $40.73
- DMAC N/A
- P/E Ratio
- ODV N/A
- DMAC N/A
- Revenue Growth
- ODV N/A
- DMAC N/A
- 52 Week Low
- ODV $1.16
- DMAC $3.19
- 52 Week High
- ODV $3.22
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- ODV 53.34
- DMAC 63.84
- Support Level
- ODV $2.73
- DMAC $6.83
- Resistance Level
- ODV $3.21
- DMAC $7.41
- Average True Range (ATR)
- ODV 0.15
- DMAC 0.43
- MACD
- ODV -0.01
- DMAC 0.03
- Stochastic Oscillator
- ODV 33.33
- DMAC 73.62
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.